Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine ER for UUI in women with OAB
NCT00143481Phase 4Completed
- Sponsor
- Viatris
- Start
- Mar 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) and urge incontinence comparing Tolterodine ER 4mg QD with Placebo (2 arms). Primary endpoint: Change in number of episodes of urgency urinary incontinence (UUI) at week 12 compared with baseline. Started Mar 2005; status: completed.
02
Drugs
tolterodine
03
Conditions
overactive bladder (OAB)urge incontinence
Beyond the preview
Go deeper on NCT00143481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143481.